Assessment of Fatigue During Radiotherapy for Breast Cancer With and Without Homeopathy Treatment

NCT ID: NCT02890316

Last Updated: 2019-04-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 64 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-07-31
• Study Completion Date: 2018-08-01

Brief Summary

To evaluate the effects of homeopathy treatment on radiotherapy-induced fatigue, cognitive and emotional functions.

Detailed Description

Sixty four female patients who underwent Chemotherapy and are planned to receive adjuvant whole breast radiation in the radiation departmental at the Sheba Medical Center, and who give a written consent for participation, will be included in the study.

Patients will undergo routine CT simulation and will receive 50 Gy in daily fractions of 2 Gy, five times a week (for total of 33 sessions during ~7 weeks, including boost of 8 fractions to the tumor bed) to the whole breast and lymphatic basins, according to the standard departmental protocol. Demographic and cancer treatment information will be collected, as well as Body mass index (BMI). At the first RT session (first assessment) and following 16-20 sessions of radiotherapy (second assessment), all patients will be evaluated for:

(i) fatigue level utilizing the Fatigue Symptom Inventory (FSI). (ii) attention performance utilizing the Pre-Pulse Inhibition (PPI) task. (iii) anxiety level utilizing both the startle response test and examining the Galvanic Skin Response (GSR) differences.

All examination will be conducted after the daily radiotherapy session. The homeopathic doctor will conduct an individual homeopathic evaluation during the second assessment meeting to all participants. According to these assessments, the pharmacist will prepare and provide 64 blinded numbered sets, 40 of which will contain the study remedy and 24 will contain the carrier only (i.e placebo).

Upon entry to the study after meeting the exclusion/inclusion criteria, a number from 1-64 will be drawn and the patient will receive the corresponding treatment.

The preparation of the homeopathic treatment (sugar globule containing the homeopathic dilution) is held in a licensed pharmacy and according to the Israeli Ministry of Health instructions of preparation. Sixty globules of sugar are wetted in the final diluted solution and dried for several minutes, and will be packed in the pharmacy to be consumed by the patients 3 times a day, 15 minutes before meal.

Placebo treatment is 1% sugar globule, similar in form and hedonic value of the aforementioned homeopathic globule.

During the 32-33 sessions of radiotherapy (third assessment), all patients will be re-assessed for the third time as before (i.e. first and second assessments). A fourth assessment to be held one month after the completion of radiotherapy.

Conditions

Breast Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Radiation therapy with Homeopathy

Patients in this arm will receive the homeopathy remedy during the adjuvant radiation therapy period, from treatment number 16 until the last assessment, 3 times every day.

Group Type: EXPERIMENTAL

Homeopathy remedy

Intervention Type: OTHER

Homeopathy remedy, prescribed by a physician and prepared by licensed pharmacy.

Radiation as adjuvant therapy for breast cancer

Intervention Type: RADIATION

Daily radiation therapy.

Radiation therapy with placebo

Patients in this arm will receive the placebo remedy during the adjuvant radiation period, from treatment number 16 until the last assessment, 3 times every day.

Group Type: PLACEBO_COMPARATOR

Radiation as adjuvant therapy for breast cancer

Intervention Type: RADIATION

Daily radiation therapy.

Interventions

Homeopathy remedy

Homeopathy remedy, prescribed by a physician and prepared by licensed pharmacy.

Intervention Type: OTHER

Radiation as adjuvant therapy for breast cancer

Daily radiation therapy.

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

1. Female patients aged at least 18 years with unilateral breast cancer following chemotherapy.

2. Planned to receive 50 Gy whole breast irradiation and lymphatic basin + boost to tumor bed.

3. Capable of giving written informed consent following the instructions of receiving the study remedy or placebo.

4. No co-morbidities known to affect radiotherapy reactions.

5. No co-existing neurological or active psychiatric chronic diseases.

6. No evidence of infection or inflammation of breast to be treated.

7. Not receiving chemotherapy during radiotherapy course. Biological or hormonal therapy will be allowed during the study.

Exclusion Criteria

1. Uncontrolled hypertension.

2. Participating in another clinical study with active treatment

3. Substance abuse.

4. Intellectual disabilities.

5. Unable to sign informed concent

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Technion, Israel Institute of Technology

OTHER

Sponsor Role: collaborator

Sheba Medical Center

OTHER_GOV

Sponsor Role: lead

Responsible Party

Dr. Merav Ben-David

Head, Breast Radiation Unit

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Merav Ben-David, MD

Role: PRINCIPAL_INVESTIGATOR

Sheba Medical Center

Locations

Merav Ben David

Ramat Gan, , Israel

Countries

Israel

References

Dolev T, Ben-David M, Shahadi I, Freed Y, Zubedat S, Aga-Mizrachi S, Brand Z, Galper S, Jacobson G, Avital A. Attention Dysregulation in Breast Cancer Patients Following a Complementary Alternative Treatment Routine: A Double-Blind Randomized Trial. Integr Cancer Ther. 2021 Jan-Dec;20:15347354211019470. doi: 10.1177/15347354211019470.

Reference Type: DERIVED

PMID: 34027702 (View on PubMed)

Other Identifiers

2370-15

Identifier Type: -

Identifier Source: org_study_id